Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study / Turner, Nicholas C.; Balmaña, Judith; Poncet, Coralie; Goulioti, Theodora; Tryfonidis, Konstantinos; Honkoop, Aafke H.; Zoppoli, Gabriele; Razis, Evangelia; Johannsson, Oskar Th; Colleoni, Marco; Tutt, Andrew N. J.; Audeh, William; Ignatiadis, Michail; Mailliez, Audrey; Trédan, Olivier; Musolino, Antonino; Vuylsteke, Peter; Juan Fita, Maria Jose; Macpherson, Iain R J; Kaufman, Bella; Manso, Luis; Goldstein, Lori J.; Ellard, Susan L; Láng, István; Jen, Kai Yu; Adam, Virginie; Litière, Saskia; Erban, John; Cameron, David A. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - (2021), p. clincanres.0310.2021. [10.1158/1078-0432.CCR-21-0310]
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study
Musolino, AntoninoWriting – Review & Editing
;
2021-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
